vs
Side-by-side financial comparison of CuriosityStream Inc. (CURI) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $19.2M, roughly 1.2× CuriosityStream Inc.). CuriosityStream Inc. runs the higher net margin — -19.7% vs -416.2%, a 396.4% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 35.8%). CuriosityStream Inc. produced more free cash flow last quarter ($3.9M vs $-69.4M). Over the past eight quarters, CuriosityStream Inc.'s revenue compounded faster (26.5% CAGR vs -10.8%).
Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
CURI vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.2M | $23.0M |
| Net Profit | $-3.8M | $-95.8M |
| Gross Margin | — | — |
| Operating Margin | -17.6% | -428.9% |
| Net Margin | -19.7% | -416.2% |
| Revenue YoY | 35.8% | 78.8% |
| Net Profit YoY | -34.6% | 25.7% |
| EPS (diluted) | $-0.07 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $19.2M | $23.0M | ||
| Q3 25 | $18.4M | $13.8M | ||
| Q2 25 | $19.0M | $14.2M | ||
| Q1 25 | $15.1M | $16.6M | ||
| Q4 24 | $14.1M | $12.9M | ||
| Q3 24 | $12.6M | $9.1M | ||
| Q2 24 | $12.4M | $7.0M | ||
| Q1 24 | $12.0M | $28.9M |
| Q4 25 | $-3.8M | $-95.8M | ||
| Q3 25 | $-3.7M | $-101.3M | ||
| Q2 25 | $784.0K | $-101.3M | ||
| Q1 25 | $319.0K | $-114.3M | ||
| Q4 24 | $-2.8M | $-128.9M | ||
| Q3 24 | $-3.1M | $-135.7M | ||
| Q2 24 | $-2.0M | $-147.0M | ||
| Q1 24 | $-5.0M | $-107.4M |
| Q4 25 | -17.6% | -428.9% | ||
| Q3 25 | -24.5% | -808.9% | ||
| Q2 25 | 2.5% | -772.2% | ||
| Q1 25 | 0.5% | -726.6% | ||
| Q4 24 | -27.4% | -1059.9% | ||
| Q3 24 | -25.8% | -1589.0% | ||
| Q2 24 | -20.6% | -1998.6% | ||
| Q1 24 | -30.4% | -394.0% |
| Q4 25 | -19.7% | -416.2% | ||
| Q3 25 | -20.4% | -735.2% | ||
| Q2 25 | 4.1% | -710.8% | ||
| Q1 25 | 2.1% | -687.6% | ||
| Q4 24 | -19.9% | -1001.2% | ||
| Q3 24 | -24.3% | -1489.5% | ||
| Q2 24 | -16.4% | -2112.6% | ||
| Q1 24 | -42.0% | -371.3% |
| Q4 25 | $-0.07 | $-0.81 | ||
| Q3 25 | $-0.06 | $-0.92 | ||
| Q2 25 | $0.01 | $-0.98 | ||
| Q1 25 | $0.01 | $-1.10 | ||
| Q4 24 | $-0.05 | $-1.27 | ||
| Q3 24 | $-0.06 | $-1.34 | ||
| Q2 24 | $-0.04 | $-1.52 | ||
| Q1 24 | $-0.09 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.3M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $41.5M | $671.4M |
| Total Assets | $75.7M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.3M | $449.9M | ||
| Q3 25 | $27.8M | $511.0M | ||
| Q2 25 | $28.1M | $459.7M | ||
| Q1 25 | $33.4M | $503.7M | ||
| Q4 24 | $32.1M | $601.5M | ||
| Q3 24 | $33.2M | $658.1M | ||
| Q2 24 | $39.5M | $691.1M | ||
| Q1 24 | $38.8M | $791.3M |
| Q4 25 | $41.5M | $671.4M | ||
| Q3 25 | $47.2M | $748.4M | ||
| Q2 25 | $49.8M | $715.3M | ||
| Q1 25 | $58.1M | $779.9M | ||
| Q4 24 | $57.8M | $872.0M | ||
| Q3 24 | $62.2M | $962.6M | ||
| Q2 24 | $64.8M | $971.1M | ||
| Q1 24 | $67.0M | $1.0B |
| Q4 25 | $75.7M | $842.1M | ||
| Q3 25 | $74.7M | $925.3M | ||
| Q2 25 | $78.7M | $898.9M | ||
| Q1 25 | $85.3M | $986.2M | ||
| Q4 24 | $86.2M | $1.2B | ||
| Q3 24 | $87.6M | $1.2B | ||
| Q2 24 | $90.9M | $1.2B | ||
| Q1 24 | $94.6M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.0M | $-69.3M |
| Free Cash FlowOCF − Capex | $3.9M | $-69.4M |
| FCF MarginFCF / Revenue | 20.5% | -301.6% |
| Capex IntensityCapex / Revenue | 0.1% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.0M | $-69.3M | ||
| Q3 25 | $4.4M | $-76.9M | ||
| Q2 25 | $2.8M | $-99.6M | ||
| Q1 25 | $1.9M | $-148.9M | ||
| Q4 24 | $3.0M | $-85.2M | ||
| Q3 24 | $2.3M | $-84.8M | ||
| Q2 24 | $2.2M | $-58.2M | ||
| Q1 24 | $666.0K | $-120.7M |
| Q4 25 | $3.9M | $-69.4M | ||
| Q3 25 | — | $-76.9M | ||
| Q2 25 | — | $-99.9M | ||
| Q1 25 | $1.8M | $-149.7M | ||
| Q4 24 | — | $-86.2M | ||
| Q3 24 | — | $-86.1M | ||
| Q2 24 | — | $-59.2M | ||
| Q1 24 | — | $-123.2M |
| Q4 25 | 20.5% | -301.6% | ||
| Q3 25 | — | -558.2% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | 12.2% | -900.1% | ||
| Q4 24 | — | -669.4% | ||
| Q3 24 | — | -945.2% | ||
| Q2 24 | — | -850.9% | ||
| Q1 24 | — | -425.7% |
| Q4 25 | 0.1% | 0.5% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.0% | 1.7% | ||
| Q1 25 | 0.5% | 4.4% | ||
| Q4 24 | 0.0% | 7.6% | ||
| Q3 24 | 0.0% | 14.0% | ||
| Q2 24 | 0.0% | 14.5% | ||
| Q1 24 | 0.0% | 8.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.56× | — | ||
| Q1 25 | 6.03× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CURI
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
